Evidence map›Paper›PMID 39711135›Full record

Trial reportJournal of clinical pharmacology2025

Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5-HT

Lauren E Thompson, Avisek Ghimire, Xia Wen, Christine Kim, Cathleen L Doherty, Brian T Buckley, Daniel W Bowles, Cindy L O'Bryant, Edgar A Jaimes, Lauren M Aleksunes and 1 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lauren E ThompsonDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0002-0297-199X
Avisek GhimireDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Xia WenEnvironmental and Occupational Health Sciences Institute, Rutgers University, Piscataway, NJ, USA.
Christine KimDepartment of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA.
Cathleen L DohertyDepartment of Earth and Planetary Sciences, Rutgers University, Piscataway, NJ, USA.
Brian T BuckleyEnvironmental and Occupational Health Sciences Institute, Rutgers University, Piscataway, NJ, USA.
Daniel W BowlesCancer Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Cindy L O'BryantCancer Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Edgar A JaimesRenal Service, Memorial Sloan Kettering Cancer Center, New York, NJ, USA.
Lauren M AleksunesEnvironmental and Occupational Health Sciences Institute, Rutgers University, Piscataway, NJ, USA.
Melanie S JoyDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI PANOS G. GEORGOPOULOS · 1988 to 2026
$47.4M
Colorado Clinical and Translational Sciences Institute (CCTSI)UM1TR004399 · NCATS · UNIVERSITY OF COLORADO DENVER · PI JANINE A HIGGINS, RONALD J. SOKOL · 2023 to 2026
$30.7M
New Jersey Alliance for Clinical Translational Science: NJ ACTSUL1TR003017 · NCATS · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI PANETTIERI, REYNOLD ALEXANDER · 2019 to 2023
$28.9M
TRAINING IN EVIRONMENTAL TOXICOLOGYT32ES007148 · NIEHS · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI Lauren M Aleksunes · 1987 to 2026
$11.4M
NRSA Training CoreTL1TR002533 · NCATS · UNIVERSITY OF COLORADO DENVER · PI CICUTTO, LISA · 2018 to 2022
$3.0M
Drug Disposition and NephrotoxicityR01GM123330 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI ALEKSUNES, LAUREN M, JOY, MELANIE S · 2018 to 2021
$2.1M
Training in Molecular and Systems ToxicologyT32ES029074 · NIEHS · UNIVERSITY OF COLORADO DENVER · PI Jared Michael Brown · 2019 to 2026
$1.1M
Pharmacokinetic and Pharmacogenomic Determinants of Cisplatin Kidney InjuryR21DK093903 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI ALEKSUNES, LAUREN M, JOY, MELANIE S · 2012 to 2013
$423k
NCATS NIH HHS TL1 TR002533NCATS NIH HHS UL1 TR003017NCATS NIH HHS UM1 TR004399NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA046934NCI NIH HHS P30 CA072720NIDDK NIH HHS R21 DK093903NIEHS NIH HHS P30 ES005022NIEHS NIH HHS T32 ES007148NIEHS NIH HHS T32 ES029074NIGMS NIH HHS R01 GM123330
6 · The paper itself

Abstract

Cisplatin is a platinum-based chemotherapeutic drug used to treat many types of cancer. The aim of this study was to develop a population pharmacokinetic model that incorporates plasma unbound and bound platinum levels. Cancer patients undergoing their first or second cycle of cisplatin-containing chemotherapy (n = 33) were prospectively randomized to receive a 5-hydroxytryptamine (5-HT

Indexed as

AntiemeticsAntineoplastic AgentsCisplatinModels, BiologicalNeoplasmsPlatinumSerotonin 5-HT3 Receptor AntagonistsAdultAgedFemaleGranisetronHumansIsoquinolinesMaleMiddle AgedOndansetronAntiemeticsAntineoplastic AgentsCisplatinGranisetronIsoquinolinesOndansetronPalonosetronPlatinumQuinuclidinesSerotonin 5-HT3 Receptor Antagonists5‐HT3 antagonistcisplatinclinical pharmacology (CPH)ondansetronpharmacometricsplatinumpopulation pharmacokinetics

Identifiers

PMID39711135
PMCPMC12116245

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.